pharmaphorum1 天
Intercept's Ocaliva approved in EU for liver disease
The European Commission has approved Intercept’s Ocaliva (obeticholic acid) for the liver disease ... a potent and selective agonist of the farnesoid X receptor (FXR), which is expressed at ...
Medpage Today on MSN3 天
Expanded Treatment Options for Primary Biliary Cholangitis Leave Open Questions
The approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in ...
Business Insider21 天
Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New ...
About Ocaliva ® (obeticholic acid) OCALIVA, a farnesoid X receptor (FXR) agonist, is indicated for the treatment of adult patients with primary biliary cholangitis (PBC) without cirrhosis or with ...
GlobalData on MSN1 个月
Intercept’s liver disease drug Ocaliva faces FDA approval delay
Intercept Pharmaceuticals will have to keep waiting for a decision about Ocaliva (obeticholic ... Ocaliva activates the ...
GlobalData on MSN4 天
Advanz Pharma’s liver disease drug pulled from European market after court hearing
This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...